IBI354

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Breast CancerLocally Advanced Unresectable or Metastatic Solid Tumors

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

1

IBI354

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

12

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

13

Tianeptine

Pfizer

Preclinical

14

Ablavar

LLantheus Medical Imaging

Preclinical

25

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

16

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

27

Naltrexone/bupropion

Novo Nordisk

Preclinical

18

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

19

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

110

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Locally Advanced Unresectable or Metastatic Solid Tumors1 trial

A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors

Recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT05636215·368 enrolled

Breast Cancer1 trial

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

Recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 3·NCT07377643·540 enrolled

Ovarian1 trial

A Multicenter, Randomized, Open-label Phase III Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT06834672·450 enrolled

Details

Drug Info

Related News